Article info

Download PDFPDF
Original Article
Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma

Authors

  • Victoria Tovar Liver Cancer Translational Research Laboratory, Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit and Pathology Department, IDIBAPS, Hospital Clínic, CIBERehd, Universitat de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Helena Cornella Liver Cancer Translational Research Laboratory, Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit and Pathology Department, IDIBAPS, Hospital Clínic, CIBERehd, Universitat de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Agrin Moeini Liver Cancer Translational Research Laboratory, Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit and Pathology Department, IDIBAPS, Hospital Clínic, CIBERehd, Universitat de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Samuel Vidal Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, USA PubMed articlesGoogle scholar articles
  • Yujin Hoshida Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA PubMed articlesGoogle scholar articles
  • Daniela Sia Liver Cancer Translational Research Laboratory, Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit and Pathology Department, IDIBAPS, Hospital Clínic, CIBERehd, Universitat de Barcelona, Barcelona, Spain Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA Gastrointestinal Surgery and Liver Transplantation Unit, National Cancer Institute, Milan, Italy PubMed articlesGoogle scholar articles
  • Judit Peix Liver Cancer Translational Research Laboratory, Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit and Pathology Department, IDIBAPS, Hospital Clínic, CIBERehd, Universitat de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Laia Cabellos Liver Cancer Translational Research Laboratory, Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit and Pathology Department, IDIBAPS, Hospital Clínic, CIBERehd, Universitat de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Clara Alsinet Liver Cancer Translational Research Laboratory, Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit and Pathology Department, IDIBAPS, Hospital Clínic, CIBERehd, Universitat de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Sara Torrecilla Liver Cancer Translational Research Laboratory, Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit and Pathology Department, IDIBAPS, Hospital Clínic, CIBERehd, Universitat de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Iris Martinez-Quetglas Liver Cancer Translational Research Laboratory, Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit and Pathology Department, IDIBAPS, Hospital Clínic, CIBERehd, Universitat de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Juan José Lozano Bioinformatic Platform, IDIBAPS, CIBERehd, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Christèle Desbois-Mouthon Sorbonne Universités, UPMC Univ Paris 06, UMR_S 938, Saint-Antoine Research Center, Paris, France INSERM UMR_S 938, Saint-Antoine Research Center, Paris, France PubMed articlesGoogle scholar articles
  • Manel Solé Liver Cancer Translational Research Laboratory, Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit and Pathology Department, IDIBAPS, Hospital Clínic, CIBERehd, Universitat de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Josep Domingo-Domenech Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, USA PubMed articlesGoogle scholar articles
  • Augusto Villanueva Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, USA PubMed articlesGoogle scholar articles
  • Josep M Llovet Liver Cancer Translational Research Laboratory, Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit and Pathology Department, IDIBAPS, Hospital Clínic, CIBERehd, Universitat de Barcelona, Barcelona, Spain Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Josep M Llovet, Liver Cancer Translational Research Laboratory, BCLC Group, IDIBAPS, Liver Unit, Hospital Clínic, University of Barcelona, Villarroel 170, Barcelona 08036, Spain; jmllovet{at}clinic.cat
View Full Text

Citation

Tovar V, Cornella H, Moeini A, et al
Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma

Publication history

  • Received March 4, 2015
  • Revised October 30, 2015
  • Accepted November 1, 2015
  • First published December 11, 2015.
Online issue publication 
February 15, 2017

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.